ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.25 and has seen 1.31 million shares traded in the recent trading session. The company, currently valued at $253.56M, closed the recent trade at $1.28 per share which meant it lost -$0.08 on the day or -5.99% during that session. The ATAI stock price is -122.66% off its 52-week high price of $2.85 and 19.53% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.75 million shares traded. The 3-month trading volume is 2.88 million shares.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.18.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Sporting -5.99% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ATAI stock price touched $1.28 or saw a rise of 18.99%. Year-to-date, ATAI Life Sciences N.V shares have moved -3.86%, while the 5-day performance has seen it change -18.56%. Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed -14.76%. Short interest in the company has seen 10.4 million shares shorted with days to cover at 3.61.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 78.67% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -368.75% off the targeted high while a plunge would see the stock gain -368.75% from the levels at last check today.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The company’s shares have gained 9.28% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -18.83%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.62% over the past 5 years. Earnings growth for 2025 is a modest 24.17% while over the next 5 years, the company’s earnings are expected to increase by 17.72%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report on 2025-Mar-16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Insiders own 8.58% of the company shares, while shares held by institutions stand at 29.18% with a share float percentage of 31.92%. Investors are also buoyed by the number of investors in a company, with ATAI Life Sciences N.V having a total of 112.0 institutions that hold shares in the company. The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7226% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.6952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF. As of Dec 31, 2024, the former fund manager holds about 0.26% shares in the company for having 511.99 shares of worth $0.65 million while later fund manager owns 408.76 shares of worth $0.52 million as of Feb 28, 2025, which makes it owner of about 0.21% of company’s outstanding stock.
